New combo therapy aims to boost rectal cancer remission without surgery
NCT ID NCT06281405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding radiotherapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (Toripalimab) can improve outcomes for people with a specific type of locally advanced rectal cancer (MSS/pMMR). About 192 participants will receive either the drug combo alone or with short-course radiation before possible surgery. The goal is to see if the added radiation leads to more complete remissions, potentially allowing some patients to avoid surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Could cutting one amino acid make rectal cancer treatment more effective?
- Can a targeted radiation combo boost rectal cancer remission?
- Can a short burst of radiation plus triple chemotherapy wipe out rectal cancer before surgery?
- Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?